Status:
RECRUITING
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Haemophilia A
Eligibility:
MALE
Brief Summary
The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any ch...
Eligibility Criteria
Inclusion
- Paediatric and adult male patients
- On-demand and prophylactic patients with haemophilia A (any severity)
- Only previously treated patients (previous FVIII replacement therapy) will be included in the study
Exclusion
- Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease
- Patients with documented presence of any FVIII inhibitor
Key Trial Info
Start Date :
November 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT06574984
Start Date
November 10 2024
End Date
December 1 2025
Last Update
December 1 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
National centre for Hamophilia
Baghdad, Iraq, 10001
2
Novo Nordisk Investigational Site
Baghdad, Iraq
3
Basrah Haemoplhilia centre
Basra, Iraq, 61001
4
Hilla Haemophilia centre
Hillah, Iraq, 51001